Pharmacogenetically based dosing of thiopurines in childhood acute lymphoblastic leukemia: Influence on cure rates and risk of second cancer

Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing: 2013 Update

(2013) M V Relling et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Second Malignant Neoplasms After Treatment of Childhood Acute Lymphoblastic Leukemia

(2013) Kjeld Schmiegelow et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing

(2011) M V Relling et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Thiopurine methyltransferase genetics is not a major risk factor for secondary malignant neoplasms after treatment of childhood acute lymphoblastic leukemia on Berlin-Frankfurt-Munster protocols

(2009) M. Stanulla et al.   BLOOD

Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study

(2009) K. Schmiegelow et al.   BLOOD

Lifelong Cancer Incidence in 47 697 Patients Treated for Childhood Cancer in the Nordic Countries

(2009) Jørgen H. Olsen et al.   JNCI-Journal of the National Cancer Institute

Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia

(2009) K Schmiegelow et al.   LEUKEMIA

Pharmacogenetics Influence Treatment Efficacy in Childhood Acute Lymphoblastic Leukemia

(2008) Marie Louise Davidsen et al.   JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY

Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study

(2008) K Schmiegelow et al.   LEUKEMIA